Mots-clés
 > MYOBASE > BIOLOGIE > biologie par discipline > biologie cellulaire > technique de biologie cellulaire > modèle cellulaire
modèle cellulaireSynonyme(s)cellular modelization ;cellule modèle ;model cell cellular models |
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) Mettre toutes les notices dans le panier Faire une suggestion Ajouter un critère de rechercheEtendre la recherche sur niveau(x) vers le bas
Generation of two iPSC lines (FAMRCi006-A and FAMRCi006-B) from patient with dilated cardiomyopathy and Emery-Dreifuss muscular dystrophy associated with genetic variant LMNAp.Arg527Pro
Perepelina K, Klauzen P, Khudiakov A, et al.
Stem cell research, 2020, 43
Self-Organizing 3D Human Trunk Neuromuscular Organoids
Faustino Martins JM, Fischer C, Urzi A, et al.
Cell stem cell, 2020, 26, 2
On-chip 3D neuromuscular model for drug screening and precision medicine in neuromuscular disease
Osaki T, Uzel SGM, Kamm RD
Nature Protocols, 2020
Cored in the act: the use of models to understand core myopathies
Fusto A, Moyle LA, Gilbert PM, et al.
Disease models & mechanisms, 2019, 12, 12
DeepNEU: Artificially Induced Stem Cell (aiPSC) and Differentiated Skeletal Muscle Cell (aiSkMC) Simulations of Infantile Onset POMPE Disease (IOPD) for Potential Biomarker Identification and Drug Discovery
Esmail S, Danter WR
Frontiers in cell and developmental biology, 2019, 7, p 325
A CTG repeat-selective chemical screen identifies microtubule inhibitors as selective modulators of toxic CUG RNA levels
Reddy K, Jenquin JR, McConnell OL, et al.
Proceedings of the national Academy of sciences of the United States of America, 2019, 116, 42
A new patient-derived iPSC model for dystroglycanopathies validates a compound that increases glycosylation of alpha-dystroglycan
Kim J, Lana B, Torelli S, et al.
EMBO reports, 2019
Using human Pompe disease-induced pluripotent stem cell-derived neural cells to identify compounds with therapeutic potential
Huang HP, Chiang W, Stone L, et al.
Human molecular genetics, 2019
Zoom sur ... la recherche dans la maladie de Steinert
Myoinfo (AFM-Téléthon), Gourdon G, Bassez G, et al.
Zoom sur ..., Savoir & Comprendre, 2019, 51
Clinical and research strategies for limb-girdle congenital myasthenic syndromes
O'Connor E, Töpf A, Zahedi RP, et al.
Annals of the New York Academy of Sciences, 2018, 1412, 1, p 102
Stem cell derived phenotypic human neuromuscular junction model for dose response evaluation of therapeutics
Santhanam N, Kumanchik L, Guo X, et al.
Biomaterials, 2018, 166, p 64
Seamless Genetic Conversion of SMN2 to SMN1 via CRISPR/Cpf1 and Single-Stranded Oligodeoxynucleotides in Spinal Muscular Atrophy Patient-Specific Induced Pluripotent Stem Cells
Zhou M, Hu Z, Qiu L, et al.
Human gene therapy, 2018, 29, 11, p 1252
Dysfunction of NaV1.4, a skeletal muscle voltage-gated sodium channel, in sudden infant death syndrome: a case-control study
Männikkö R, Wong L, Tester DJ, et al.
Lancet (London, England), 2018, 391, 10129, p 1483
Test of Antifibrotic Drugs in a Cellular Model of Fibrosis Based on Muscle-Derived Fibroblasts from Duchenne Muscular Dystrophy Patients
Zanotti S, Mora M
Methods in molecular biology, 2018, 1687, p 205
Measurement of Chaperone-Mediated Effects on Polyglutamine Protein Aggregation by the Filter Trap Assay
van Waarde-Verhagen MAWH, Kampinga HH
Methods in molecular biology, 2018, 1709, p 59
SMAD6 overexpression leads to accelerated myogenic differentiation of LMNA mutated cells
Janin A, Bauer D, Ratti F, et al.
Scientific Reports, 2018, 8, 1
Modeling the Pathogenesis of Charcot-Marie-Tooth Disease Type 1A Using Patient-Specific iPSCs
Shi L, Huang L, He R, et al.
Stem cell reports, 2018, 10, 1, p 120
Zoom sur ... la recherche dans la maladie de Steinert
Myoinfo (AFM-Téléthon), Gourdon G, Bassez G, et al.
Zoom sur ..., Savoir & Comprendre, 2018, 49 p.
La recherche animale : une étape sur le chemin du médicament : Le dossier 01
VLM. Vaincre les myopathies, 2017, 182, p .20-21
Criblage de molécules : En quête de traitements... : Le dossier 01
Dupuy-Maury F
VLM. Vaincre les myopathies, 2017, 181, p.19-23
Sarcoglycanopathies : un premier colloque organisé par Généthon
Dupuy-Maury F
VLM. Vaincre les myopathies, 2017, 180, p. 07-09
Facioscapulohumeral Muscular Dystrophy
DeSimone AM, Pakula A, Lek A, et al.
Comprehensive Physiology, 2017, 7, 4, p 1229
Immortalized human myotonic dystrophy muscle cell lines to assess therapeutic compounds
Arandel L, Polay-Espinosa M, Matloka M, et al.
Disease models & mechanisms, 2017, 10, 4, p 487
Therapeutic strategies for spinal muscular atrophy: SMN and beyond
Bowerman M, Becker CG, Yanez-Munoz RJ, et al.
Disease models & mechanisms, 2017, 10, 8, p 943
Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model
Ando S, Funato M, Ohuchi K, et al.
European journal of pharmacology, 2017, 814, p 161
